Cabot Corporation (CBT) — RQD Stock Rating Cockpit

$74.43 +0.79% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $74.39

Cabot Corporation (CBT) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $3.81B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CBT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cabot Corporation (NYSE: CBT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $74.43 (+0.79% 1D, market cap $3.81B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Across 270 tracked Materials issuers, CBT ranks #25 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CBT compare to AVNT and VVV in the Materials sector?
▼

Within the Materials sector (Major Chemicals), CBT carries a Roarable C (64/100 RQD), trailing P/E of 11.5x, gross margin of 25.3%, and ROIC of 22.3%. By comparison, AVNT (Avient Corporation) holds a C+ grade (67/100 RQD, P/E 48.0x, ROIC 3.7%, cap $3.93B) and VVV (Valvoline Inc.) posts a D grade (45/100 RQD, P/E 19.6x, ROIC 16.5%, cap $4.13B). Among the 5-stock peer group, CBT leads on earnings multiple (11.5x) while CBT leads on capital efficiency (22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CBT?
▼

Per CBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000016040), Cabot Corporation generated $3.71B in revenue (-7.0% YoY), $331.0M in net income, and $391.0M in free cash flow against $3.76B in total assets and $854.0M in total debt. Key quantitative strengths: Strong cash generator (25% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $74.39 (-0.05%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 10.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C-
Cash (16)Whales (6)SEC (15)Macro (9)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$99 Bull$76 Base$60 Bear
📬 FREE CBT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CBT)Realized 20D OHLCV Swing Band: ±4.1%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY CBT SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.5% FCF Margin ($391.0M FCF) & 25.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$74.26-1.1% Next Q
Q2 (-2Q)
59
Grade C$73.46-0.8% Next Q
Q3 (-1Q)
61
Grade C$72.88+2.1% Next Q
Current
64
Grade C$74.43+1.1% Hist 90D α
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CBT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, CBT faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 22.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.73) or 200D SMA ($79.54) invalidates the momentum regime and cuts Target Base ($76.44) toward Bear Floor ($59.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CBT Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
40.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE44% OF RANGE
L: $58$74.43H: $95
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (25% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on CBT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

22.3% ROIC with 25.3% gross margin and 10.25% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (55)

24/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like CBT
  • ✓Strong cash generator (25% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CBT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.87%▲ RESISTANCE BREAKOUT
2026-11-02O $73.77H $74.43L $73.77C $74.43VOL 392.3K
RES: $73.81SUP: $71.59SMA50: $77.73SMA200: $79.54
$96.09$89.63$83.17$76.71$70.26RES $73.81SUP $71.59$74.432026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
1.6%/yr Implied 5Y Growth

vs. -7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CBT)

Materials Rank #25 of 270 ⚔️ AVNT vs CBT Full Matrix →

1. Head-to-Head Materials Peer Comparison (CBT vs. AVNT, VVV, PRM, MEOH)

Industry: Major Chemicals (67 Tracked Issuers)

Across 270 tracked Materials securities in the Roarable RQD universe, Cabot Corporation (CBT) ranks #25 by composite RQD confidence (64/100, grade C) and #86 by equity capitalization ($3.81B). Within this direct 5-issuer industry benchmark cohort, CBT leads on earnings valuation at 11.5x trailing P/E, while CBT leads on capital efficiency and profitability with 22.3% ROIC and 25.3% gross margin. AVNT currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with CBT at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CBT ACTIVE
Cabot Corporation
C 64/100 11.5x 25.3% 22.3% +0.79% $3.81B Benchmark Subject
AVNT
Avient Corporation
C+ 67/100 48.0x 31.2% 3.7% -0.09% $3.93B /avnt-vs-cbt →
VVV
Valvoline Inc.
D 45/100 19.6x 38.5% 16.5% -0.28% $4.13B /vvv-vs-cbt →
PRM
Perimeter Solutions SA
D 44/100 — 57.5% -10.8% -1.61% $4.67B /prm-vs-cbt →
MEOH
Methanex Corporation
C- 60/100 — — — +14.04% $4.86B /meoh-vs-cbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000016040

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Cabot Corporation (CBT) reported GAAP revenue of $3.71B (-7.0% vs. FY2024 revenue of $3.99B , and -5.5% cumulative change since FY2023) , GAAP net income of $331.0M, operating cash flow of $665.0M, and free cash flow of $391.0M (-13.3% YoY). On the balance sheet, CBT closed FY2025 with $3.76B in total assets against $854.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $3.71B $331.0M $665.0M $391.0M $3.76B $854.0M
FY2024 (FY) 2024-09-30 $3.99B $380.0M $692.0M $451.0M $3.64B $1.09B
FY2023 (FY) 2023-09-30 $3.93B $445.0M $595.0M $595.0M — —

3. CBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cabot Corporation (NYSE: CBT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $74.43 (+0.79% 1D, market cap $3.81B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Across 270 tracked Materials issuers, CBT ranks #25 in composite RQD confidence.

How does CBT compare to AVNT and VVV in the Materials sector?

Within the Materials sector (Major Chemicals), CBT carries a Roarable C (64/100 RQD), trailing P/E of 11.5x, gross margin of 25.3%, and ROIC of 22.3%. By comparison, AVNT (Avient Corporation) holds a C+ grade (67/100 RQD, P/E 48.0x, ROIC 3.7%, cap $3.93B) and VVV (Valvoline Inc.) posts a D grade (45/100 RQD, P/E 19.6x, ROIC 16.5%, cap $4.13B). Among the 5-stock peer group, CBT leads on earnings multiple (11.5x) while CBT leads on capital efficiency (22.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CBT?

Per CBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000016040), Cabot Corporation generated $3.71B in revenue (-7.0% YoY), $331.0M in net income, and $391.0M in free cash flow against $3.76B in total assets and $854.0M in total debt. Key quantitative strengths: Strong cash generator (25% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CBT trading relative to its 50-day, 200-day, and 52-week technical levels?

CBT last traded at $74.43 (+0.79% on volume of 664,030 shares), positioning the stock -4.25% below its 50-day simple moving average ($77.73) and -6.42% below its 200-day simple moving average ($79.54). Across its 52-week range of $58.33 to $94.53, CBT sits at the 44.5% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±4.1% ($71.38 to $77.48).

CBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CBT stock right now?

Cabot Corporation (CBT) currently earns a Roarable Rating of C (Hold — HOLD) with 64/100 RQD Confidence. Solid 25% profit margin (22% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.

What is CBT's 12-month price target and RQD AI Jury consensus?

CBT's 12-month base price target is $76.44 (range $59.62 to $99.26), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CBT — Cabot Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CBT scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The Fundamental Cash Engine pillar scores 16 of 20, supported by ROIC of 22.3% and an FCF yield of 10.25%, which is the strongest component of the rating and indicates the business generates substantial returns on invested capital and cash relative to its market value. The Insider Conviction pillar scores 18 of 20 on SEC Form 4 and Congressional PTR cluster flow, the highest pillar score, suggesting insider-level activity has been comparatively supportive. The Forensic Balance Sheet pillar scores 15 of 20 with an Altman Z of 2.5, Piotroski F of 7/9, and Debt/Equity of 0.54, pointing to a moderately sound but not pristine balance sheet. The Macro Regime Fit pillar scores 9 of 20, reflecting a Beta of 1.0 and sector sensitivity, meaning the stock's exposure to broader market and sector cycles is a meaningful drag on the score. The Whale 13F Flow pillar scores only 6 of 20, indicating institutional accumulation and options positioning provide the weakest support in the rating. Taken together, the sources frame CBT as a fairly valued, balanced-risk setup: the upside case rests on cash generation and insider signals, while the score is held back by macro sensitivity and weak institutional flow. This is an analytical framing of the source data, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
73.85$3.81B11.510.75.26.412.52%1.0$58.33 - $94.5322.3%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$3713.0M$621.0M$331.0MN/A$391.0M$230.0M$854.0M
FY 2024$3994.0M$614.0M$380.0MN/A$451.0M$183.0M$1089.0M
FY 2023$3931.0M$526.0M$445.0MN/A$595.0MN/AN/A

Per the market data, gross margin is 25.3%, operating margin 16.7%, and net margin 8.9%, with ROIC of 22.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 7/9, with Debt/Equity of 0.54. Reported revenue and net income declined from FY 2024 to FY 2025 and from FY 2023 to FY 2024, while debt fell from $1089.0M to $854.0M over the same window. Full-period EPS is Not available in source data beyond the TTM figure.

Open Questions

  • What are the specific product lines, end markets, and revenue mix driving the Materials/Major Chemicals classification?
  • What explains the decline in revenue and net income across FY 2023 to FY 2025, and what are the drivers of the reduced debt?
  • What are the individual SEC Form 4 and 13F transactions underlying the Insider Conviction and Whale Flow pillar scores?
  • What is the analyst rating distribution behind the $87.80 consensus price target referenced in the news feed?
  • Which supply-chain dependencies, if any, link CBT to upstream or downstream companies?

CBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cabot Corporation (CBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CBT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CBT Bull vs. Bear Conversation Board — What's Your Call at $74.43?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CBT 🐻 50% BEARISH CONVICTION
1. Pick Your Side on CBT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $79.76 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CBT (C • RQD 64/100) a Buy at $73.85?

Welcome to the CBT (Cabot Corporation) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Major Chemicals. Bulls point to capital efficiency (22.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $56.13 (-24.0%)
Spot @ $73.85

Pump the brakes on CBT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CBT, but look at what you are paying: 11.5x trailing P/E with 25.3% gross margins. Unless Cabot Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $93.79 (+27.0%)
Spot @ $73.85

CBT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CBT, the market is fixating on short-term headline noise in Major Chemicals and ignoring the balance sheet and cash flow trajectory. At $73.85 (52-wk range $58.33 - $94.53), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%